Shanghai Shen Lian Biomedical Corporation

Equities

688098

CNE100003P17

Pharmaceuticals

End-of-day quote Shanghai S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
5.05 CNY +1.20% Intraday chart for Shanghai Shen Lian Biomedical Corporation +6.99% -32.49%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Shanghai Shen Lian Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Shen Lian Biomedical Gets Nod for Two Pig Virus Detection Kits MT
Shanghai Shen Lian Biomedical Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Shen Lian Biomedical Obtains Production License, GMP Certificate MT
Shanghai Shen Lian Biomedical Corporation Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Shen Lian Biomedical Forms Tie-up to Develop African Swine Fever Vaccine MT
Certain A Shares of Shanghai Shen Lian Biomedical Corporation are subject to a Lock-Up Agreement Ending on 16-OCT-2023. CI
Shanghai Shen Lian Biomedical Corporation Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Shen Lian Biomedical Passes Regulatory Inspection MT
Shen Lian Biomedical's Bovine Vaccine Passes Regulatory Evaluation MT
Shanghai Shen Lian Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Shanghai Shen Lian Biomedical Ties Up with Caremed Biomedical to Set Up Joint Venture MT
Shanghai Shen Lian Biomedical Corporation Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Shen Lian Biomedical Gets Marketing Approval for Pig Vaccine in China MT
Shanghai Shen Lian Biomedical Corporation Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Certain A Shares of Shanghai Shen Lian Biomedical Corporation are subject to a Lock-Up Agreement Ending on 16-OCT-2022. CI
Shanghai Shen Lian Biomedical Corporation Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Shanghai Shen Lian Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Shanghai Shen Lian Biomedical Corporation Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Shanghai Shen Lian Biomedical Corporation Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Shanghai Shen Lian Biomedical Corporation Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Shanghai Shen Lian Biomedical Corporation Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Shanghai Shen Lian Biomedical Corporation Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Tarsus Pharmaceuticals and LianBio Announce Strategic Partnership to Develop and Commercialize TP-03 in Greater China for the Treatment of Demodex Blepharitis and Meibomian Gland Disease CI
Shanghai Shen Lian Biomedical Corporation Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Chart Shanghai Shen Lian Biomedical Corporation
More charts
Shanghai Shen Lian Biomedical Corp is a China-based company mainly engaged in the research, development, production and sales of veterinary biological products. The Company is committed to the research & development of foot and mouth disease vaccines, which are used to protect animals from foot and mouth diseases. The Company's main product are swine foot and mouth disease vaccines, and it also provides cattle foot and mouth disease vaccines, other swine vaccines, and other veterinary diagnostic reagents. The Company mainly sells its products within domestic market.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 688098 Stock
  4. News Shanghai Shen Lian Biomedical Corporation
  5. Shen Lian Biomedical Obtains Production License, GMP Certificate